Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and d… Read more
Praxis Precision Medicines Inc (PRAX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.188x
Based on the latest financial reports, Praxis Precision Medicines Inc (PRAX) has a cash flow conversion efficiency ratio of -0.188x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-64.74 Million) by net assets ($343.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Praxis Precision Medicines Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Praxis Precision Medicines Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Praxis Precision Medicines Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Praxis Precision Medicines Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zurn Elkay Water Solutions Corporation
NYSE:ZWS
|
0.064x |
|
China Shipbuilding Industry Co Ltd
SHG:601989
|
-0.021x |
|
Arrow Electronics Inc
NYSE:ARW
|
0.030x |
|
Federal Home Loan Mortgage Corp Pref Variable Non Cumulative
OTCQB:FMCCN
|
0.037x |
|
SM Investments Corporation
PINK:SVTMF
|
0.031x |
|
Han'S Laser Tech A
SHE:002008
|
-0.007x |
|
Hangzhou Chang Chuan Technology Co Ltd
SHE:300604
|
0.036x |
|
Terex Corporation
NYSE:TEX
|
0.098x |
Annual Cash Flow Conversion Efficiency for Praxis Precision Medicines Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Praxis Precision Medicines Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $445.45 Million | $-131.76 Million | -0.296x | +81.46% |
| 2023-12-31 | $69.67 Million | $-111.14 Million | -1.595x | +34.39% |
| 2022-12-31 | $76.11 Million | $-185.04 Million | -2.431x | -389.60% |
| 2021-12-31 | $250.81 Million | $-124.55 Million | -0.497x | -171.27% |
| 2020-12-31 | $287.46 Million | $-52.62 Million | -0.183x | +77.60% |
| 2019-12-31 | $40.11 Million | $-32.79 Million | -0.817x | +42.09% |
| 2018-12-31 | $14.68 Million | $-20.72 Million | -1.411x | -- |